Centre bans 16 fixed dose combination drugs, including antibiotics, painkillers, skin meds
The Union government banned 16 fixed dose combination (FDC) drugs with immediate nationwide effect, prohibiting their manufacture, sale, distribution, and supply for human use.
The decision was notified under Section 26A of the Drugs and Cosmetics Act, 1940, following a Supreme Court direction to review irrational drug combinations.
Banned combinations include antibiotic FDCs such as Amoxicillin + Serratiopeptidase, Amoxicillin + Cloxacillin, Cefadroxyl + Probenecid, and Cefuroxime + Serratiopeptidase.
Other banned drugs span antispasmodics, pain-management combinations (e.g., Acetyl Salicylic Acid + Ethoheptazine), and dermatological formulations.
The Drugs Technical Advisory Board (DTAB) constituted an expert committee that found these 16 FDCs lacked therapeutic justification and posed risks including promotion of antibiotic resistance.
Fixed Dose Combinations (FDCs) and Drug Regulation
FDCs are pharmaceutical products combining two or more active drugs in a single formulation. While rational FDCs improve patient compliance and efficacy, irrational combinations — those without proven additive or synergistic therapeutic benefit — can cause harm by exposing patients to unnecessary drug components and side effects.
Key Details
- The Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare is the national regulatory body for drugs in India.
- Under Section 26A of the Drugs and Cosmetics Act, 1940, the Central Government can prohibit the manufacture, sale, or distribution of any drug "in the interest of the public" if it is deemed to involve risk to human beings.
- DTAB (Drugs Technical Advisory Board) is the statutory apex body advising the central and state governments on technical matters arising under the Act.
- Earlier, in 2016, the government banned 344 FDCs following the Kokate Committee report; the Supreme Court upheld the government's power to ban FDCs in Pfizer Ltd. v. Union of India (2017).
The current ban of 16 FDCs follows the same legal framework — Supreme Court direction → expert committee review → Section 26A notification — reinforcing the state's public health regulatory role under the Drugs and Cosmetics Act.
Antibiotic Resistance (AMR) — A Global Public Health Emergency
Antibiotic resistance occurs when bacteria evolve mechanisms to survive exposure to drugs designed to kill them. Irrational use of antibiotics — including through irrational FDC combinations — is a leading driver of antimicrobial resistance (AMR).
Key Details
- The World Health Organization (WHO) declared AMR one of the top 10 global public health threats facing humanity.
- India is among the world's largest consumers of antibiotics, and sub-therapeutic or unjustified antibiotic exposure via FDCs accelerates resistance.
- India's National Action Plan on AMR (2017–2021) aligned with the WHO Global Action Plan on AMR (2015), focusing on surveillance, rational antibiotic use, infection prevention, and research.
- ICMR (Indian Council of Medical Research) publishes annual AMR surveillance reports tracking resistance patterns across pathogens.
Banning antibiotic FDC combinations without proven therapeutic value directly implements the "rational antibiotic use" pillar of India's AMR strategy and the WHO recommendations.
Drugs and Cosmetics Act, 1940 — Regulatory Framework
The Drugs and Cosmetics Act, 1940, is the primary legislation governing the import, manufacture, distribution, and sale of drugs and cosmetics in India. It established a dual regulatory structure — Central (for imports and new drugs) and State (for manufacturing licences and distribution).
Key Details
- Section 26A empowers the Central Government to prohibit drugs in the public interest — the provision used for FDC bans.
- Amended multiple times; in 2008, provisions for clinical trial oversight were strengthened.
- The New Drugs and Clinical Trials Rules, 2019, further reformed the framework, reducing approval timelines and regulating academic clinical trials.
- The Drug Price Control Order (DPCO) under the Essential Commodities Act, 1955 governs pricing of essential medicines.
The ban invokes the Central Government's powers under Section 26A — a recurring theme in UPSC questions on drug regulation and federalism in health governance.
- 16 FDCs banned in this notification
- Legal basis: Section 26A, Drugs and Cosmetics Act, 1940
- Advisory body: DTAB (Drugs Technical Advisory Board) expert committee
- Regulator: CDSCO under Ministry of Health and Family Welfare
- Precedent: 2016 ban of 344 FDCs (Kokate Committee); upheld by Supreme Court in Pfizer Ltd. v. Union of India (2017)
- India's AMR National Action Plan: 2017–2021 (aligned with WHO Global Action Plan 2015)
- WHO declared AMR one of top 10 global public health threats
- Serratiopeptidase (an enzyme used in FDC combinations) has been a repeated target of Indian FDC bans for lack of proven therapeutic benefit